Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBIT Margin: 2011-2025

Historic EBIT Margin for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to 44.66%.

  • Catalyst Pharmaceuticals' EBIT Margin rose 510.00% to 44.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 44.76%, marking a year-over-year increase of 697.00%. This contributed to the annual value of 39.68% for FY2024, which is 1788.00% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' EBIT Margin stood at 44.66%, which was down 1.28% from 45.24% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year EBIT Margin high stood at 53.79% for Q2 2022, and its period low was -36.21% during Q3 2023.
  • Over the past 3 years, Catalyst Pharmaceuticals' median EBIT Margin value was 44.21% (recorded in 2024), while the average stood at 34.58%.
  • Its EBIT Margin has fluctuated over the past 5 years, first slumped by 8,007bps in 2023, then skyrocketed by 7,577bps in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' EBIT Margin stood at 33.26% in 2021, then surged by 1,743bps to 50.70% in 2022, then slumped by 1,299bps to 37.71% in 2023, then spiked by 660bps to 44.31% in 2024, then spiked by 510bps to 44.66% in 2025.
  • Its EBIT Margin stands at 44.66% for Q3 2025, versus 45.24% for Q2 2025 and 44.81% for Q1 2025.